β-adrenoceptor blockers and pulmonary function in the general population: The Rotterdam Study

British Journal of Clinical Pharmacology

Volumn 77, Issue 1, 2014, Pages 190-200

  Loth, Daan W ^a,b   Brusselle, Guy G ^c   Lahousse, Lies ^a,c   Hofman, Albert ^a   Leufkens, Hubert G M ^d   Stricker, Bruno H ^a,b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Inspectorate of Health Care   (Netherlands)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

adrenoceptor blockers FEV1; epidemiology; FEV1: FVC; FVC; population studies; spirometry

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; LUNG FUNCTION TEST; MALE; NETHERLANDS; POPULATION; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; SIDE EFFECT; SPIROMETRY; DRUG EFFECTS; MIDDLE AGED; VERY ELDERLY; VITAL CAPACITY;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; VITAL CAPACITY;

EID: 84887260160     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12181     Document Type: Article

References (35)

1. Benson MK, Berrill WT, Cruickshank JM, Sterling GS,. A comparison of four beta-adrenoceptor antagonists in patients with asthma. Br J Clin Pharmacol 1978; 5: 415-419.
2. Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW,. Heart failure and chronic obstructive pulmonary disease: an ignored combination? Eur J Heart Fail. 2006; 8: 706-711.
3. Huiart L, Ernst P, Suissa S,. Cardiovascular morbidity and mortality in COPD. Chest 2005; 128: 2640-2646.
4. Mascarenhas J, Azevedo A, Bettencourt P,. Coexisting chronic obstructive pulmonary disease and heart failure: implications for treatment, course and mortality. Curr Opin Pulm Med 2010; 16: 106-111.
5. Johnston AK, Mannino DM, Hagan GW, Davis KJ, Kiri VA,. Relationship between lung function impairment and incidence or recurrence of cardiovascular events in a middle-aged cohort. Thorax 2008; 63: 599-605.
6. Hannink JD, van Helvoort HA, Dekhuijzen PN, Heijdra YF,. Heart failure and COPD: partners in crime? Respirology 2010; 15: 895-901.
7. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA, Torch Clinical Endpoint Committee. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007; 62: 411-415.
8. WHO. Global burden of disease. 2004.
9. Salpeter SS, Ormiston T, Salpeter E, Poole P, Cates C,. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002; (2): CD003566.
10. Salpeter SR, Ormiston TM, Salpeter EE,. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann Intern Med 2002; 137: 715-725.
11. Rutten FH, Zuithoff NP, Hak E, Grobbee DE, Hoes AW,. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170: 880-887.
12. Sirak TE, Jelic S, Le Jemtel TH,. Therapeutic update: non-selective beta- and alpha-adrenergic blockade in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol 2004; 44: 497-502.
13. Hofman A, Grobbee DE, de Jong PT, van den Ouweland FA,. Determinants of disease and disability in the elderly: the Rotterdam Elderly Study. Eur J Epidemiol 1991; 7: 403-422.
14. Hofman A, van Duijn CM, Franco OH, Ikram MA, Janssen HL, Klaver CC, Kuipers EJ, Nijsten TE, Stricker BH, Tiemeier H, Uitterlinden AG, Vernooij MW, Witteman JC,. The Rotterdam Study: 2012 objectives and design update. Eur J Epidemiol 2011; 26: 657-686.
15. WHO Collaborating Centre for Drug Statistics Methodology. ATC classification index with DDDs. 2009. Available at: http://www.whocc.no/atc-ddd- index/ (last accessed December 2010).
16. Celli BR, MacNee W, Ats Ers Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004; 23: 932-946.
17. van Durme YM, Verhamme KM, Stijnen T, van Rooij FJ, Van Pottelberge GR, Hofman A, Joos GF, Stricker BH, Brusselle GG,. Prevalence, incidence, and lifetime risk for the development of COPD in the elderly: the Rotterdam study. Chest 2009; 135: 368-377.
18. From the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD). 1997. Available at: http://www.goldcopd.org (last accessed December 2010).
19. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, Gold Scientific Committee. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001; 163: 1256-1276.
20. Remme WJ, Swedberg K, Task Force for the Diagnosis and Treatment of Chronic Heart Failure European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001; 22: 1527-1560.
21. Bleumink GS, Knetsch AM, Sturkenboom MC, Straus SM, Hofman A, Deckers JW, Witteman JC, Stricker BH,. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J 2004; 25: 1614-1619.
22. Kardys I, Deckers JW, Stricker BH, Vletter WB, Hofman A, Witteman J,. Distribution of echocardiographic parameters and their associations with cardiovascular risk factors in the Rotterdam Study. Eur J Epidemiol 2010; 25: 481-490.
23. R Development Core Team. R: a language and environment for statistical computing. 2008. Available at: http://www.R-project.org (last accessed December 2010).
24. Martinez FJ, Donohue JF, Rennard SI,. The future of chronic obstructive pulmonary disease treatment-difficulties of and barriers to drug development. Lancet 2011; 378: 1027-1037.
25. Donohue JF,. Minimal clinically important differences in COPD lung function. COPD 2005; 2: 111-124.
26. Schnabel E, Nowak D, Brasche S, Wichmann HE, Heinrich J,. Association between lung function, hypertension and blood pressure medication. Respir Med 2011; 105: 727-733.
27. Jabbour A, Macdonald PS, Keogh AM, Kotlyar E, Mellemkjaer S, Coleman CF, Elsik M, Krum H, Hayward CS,. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol 2010; 55: 1780-1787.
28. Çamsari A, Arikan S, Avan C, Kaya D, Pekdemir H, Cicek D, Kiykim A, Sezer K, Akkus N, Alkan M, Aydogdu S,. Metoprolol, a beta-1 selective blocker, can be used safely in coronary artery disease patients with chronic obstructive pulmonary disease. Heart Vessels 2003; 18: 188-192.
29. Chang CL, Robinson SC, Mills GD, Sullivan GD, Karalus NC, McLachlan JD, Hancox RJ,. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 2011; 66: 764-768.
30. Zvezdin B, Milutinov S, Kojicic M, Hadnadjev M, Hromis S, Markovic M, Gajic O,. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest 2009; 136: 376-380.
31. Rabe KF, Wedzicha JA,. Controversies in treatment of chronic obstructive pulmonary disease. Lancet 2011; 378: 1038-1047.
32. Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM,. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 2001; 37: 1950-1956.
33. Short PM, Lipworth SI, Elder DH, Schembri S, Lipworth BJ,. Effect of {beta} blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011; 342: d2549.
34. Kazani S, Israel E,. Treatment with beta blockers in people with COPD. BMJ 2011; 342: d2655.
35. Sjahid SI, van der Linden PD, Stricker BH,. Agreement between the pharmacy medication history and patient interview for cardiovascular drugs: the Rotterdam elderly study. Br J Clin Pharmacol 1998; 45: 591-595.